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ABSTRACT
During the late 1990s, increases in referrals to the national reference laboratory of Streptococcus
pyogenes isolates from injecting drug users (IDUs) with severe soft tissue infection indicated an
emerging problem in the UK, later conﬁrmed during the 2003–2004 European enhanced surveillance
(Strep-EURO) programme. In light of these ﬁndings, further analyses were undertaken in an attempt
to understand the reasons behind this increase in referrals. Single and multivariable analyses were
undertaken to compare clinical, microbiological and demographic characteristics of IDUs diagnosed
with severe S. pyogenes infection during the 2003–2004 enhanced surveillance study with those of
other cases arising during this same period. Temporal and spatial analyses were undertaken for
IDUs to identify clustering, as a means of understanding the transmission dynamics underpinning
this increase. Infections in IDUs were spread across the UK, with some concentration in northern
England and London. IDUs presented with a wide range of clinical manifestations, including
pneumonia, which was found to be signiﬁcantly more common in IDUs (OR 3.00) than in other
cases. Marked differences in type distributions were found between IDUs and other cases, in
particular the concentration of emm ⁄M83 (22% of IDUs, 2% of non-IDUs). These ﬁndings indicate
that an epidemic of severe S. pyogenes infections in IDUs occurred in the UK, peaking in 2003. The
explanation for this rise remains unclear.
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INTRODUCTION
By virtue of their injecting behaviour, and as a
result of indirect factors such as poor living
conditions, injecting drug users (IDUs) are
particularly vulnerable to life-threatening acute
and chronic infections [1]. Since the end of the
1990s, a number of unusual outbreaks of severe
bacterial infections in injecting drug users in the
UK have been noted, including methicillin-resis-
tant Staphylococcus aureus soft tissue infection,
wound botulism, tetanus and other clostridial
infections [2–5]. Isolate referrals to the national
streptococcal reference laboratory over the past
decade involved a disproportionate increase in
Streptococcus pyogenes isolates from IDUs,with 15%
of all invasive isolates emanating from IDUs by
2002 [6]. Although biases in referral patterns or
information concerning risk factors provided in
light of the aforementioned outbreaks in IDUsmay
have explained this increase, the surveillance
undertaken during 2003–2004 as part of the 2003–
2004 European enhanced surveillance (Strep-
EURO) programme provided ﬁrmer evidence for
the importance of IDUs as a group at risk for severe
S. pyogenes infections, with one in ﬁve of UK cases
identiﬁed as an IDU [7,8]. To further understand
the reasons behind this increase in IDU-related
severe S. pyogenes infection, detailed analyses of
clinical andmicrobiological characteristics of cases
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among IDUswere compared to those of other cases
identiﬁed during the same period.
MATERIALS AND METHODS
Data collection and deﬁnitions
In accordance with the Strep-EURO programme objectives,
enhanced surveillance of severe S. pyogenes disease was
initiated in the UK between 1 January 2003 and 31 December
2004 [9]. Cases were deﬁned according to the US deﬁnition,
i.e. S. pyogenes isolated from a sterile site [10]. Cases where
S. pyogenes was isolated from a non-sterile site were also
included if patients exhibited clinical signs of streptococcal
toxic shock syndrome (STSS) or another severe status (pneu-
monia, necrotizing fasciitis, puerperal sepsis, meningitis or
septic arthritis). Details of case ascertainment and microbio-
logical characterization can be found elsewhere [7]. Referring
laboratories were sent a study questionnaire to obtain further
information on the demographic proﬁle of the patient, risk
factors, disease presentation, markers of clinical severity and
outcome. A selection of standard risk factors were included
on the questionnaire, including injecting drug use, along with
a free-text box for clinicians to note any other factors which
may have predisposed to severe S. pyogenes infection (http://
www.hpa.org.uk/hpa/inter/strep-EURO.htm).
Statistical analysis
Data were extracted for statistical analysis into STATA
statistical software (Stata Corporation, College Station, TX,
USA). Descriptive statistics were undertaken for conﬁrmed
cases, with information on risk factors supplied via the study
questionnaire. Chi-square and Kruskal–Wallis tests were used
to test for statistical signiﬁcance of differences between
subgroups. Stepwise unconditional logistic regression analysis
was undertaken to examine the independence of explanatory
variables in the development of outcomes of interest, with the
likelihood ratio test being used to evaluate the signiﬁcance of
explanatory variables within each model. MapInfo Profes-
sional (version 8.0; MapInfo Corporation, Troy, NY, USA) was
used to map the geographical distribution of cases and to
calculate the distances between them.
RESULTS
Overview of cases identiﬁed
Information concerning patient risk factors was
available for 2298 (61%) of the 3765 cases of
severe S. pyogenes infection reported by laborato-
ries across the UK in 2003 and 2004. These
patients had a sex distribution similar to that of
other cases (55% vs. 53% male; v2 (1 df) = 2.36;
p 0.125), although they were slightly younger
(median age 45 vs. 50 years; Kruskal–Wallis
v2 (1 df) = 5.63; p 0.018) and more likely to have
a winter onset of infection (December–April, 53%
vs. 49%; v2 (1 df) = 4.41; p 0.036). Strain charac-
teristics were similar between the two groups
(ranking of emm ⁄M types and prevalence of
erythromycin resistance).
Among the 2298 cases for whom risk factor
information was available, 459 (20%) were
recorded as being IDUs. The number of cases
among IDUs almost halved between 2003 and
2004, from 300 (24%) to 159 (15%; v2 (1 df) =
32.76; p <0.001), whereas the number of non-IDU
cases remained approximately the same (928 and
911 in 2003 and 2004, respectively). Three-quar-
ters of the IDUs were male (74%; 338) as com-
pared to 50% of other cases (928; v2 (1 df) = 79.73;
p <0.001). The age distribution of IDUs was
markedly different from that of other cases, even
that of young adults (Fig. 1). Just over half (52%)
of 15–44-year-old patients were IDUs. Female
IDUs were younger (median 27 years; range
17–45 years) than male IDUs (median 32 years;
range 17–54 years; Kruskal–Wallis v2 (1 df) =
34.92; p <0.001) (Fig. 1). IDUs were less ethnically
diverse than non-IDUs, 99% being white
(296 ⁄ 299), as compared to 94% of non-IDUs being
white (v2 (3 df) = 14.03; p 0.003).
Seasonal patterns of infection
The seasonal inﬂux of severe S. pyogenes infections
in 2003 was similar in IDUs and non-IDUs, with
both populations showing nearly simultaneous
upward and downward inﬂections (Fig. 2). How-
ever, a springpeakwas not evident in IDUs in 2004,
and there was a general downward trend during
this period. A distinct peak in IDU cases was
evident between September and November 2003.
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Fig. 1. Age and sex distribution of severe Streptococcus
pyogenes infections diagnosed in injecting drug users
(IDUs) and non-IDUs, UK 2003–2004.
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Geographical and temporal distribution of cases
All countries within the UK reported cases of
severe S. pyogenes infection in IDUs during 2003
and 2004, although IDUs constituted substantially
higher proportions of all cases in England (21%)
and Scotland (16%) than in Wales (4%) or
Northern Ireland (3%). Within England, cases
involving IDUs were most highly concentrated in
the north of the country (Fig. 3), especially within
the Yorkshire and the Humber regions, where
44% of all cases involved IDUs in 2003–2004,
rising to nearly half (47%) of all cases in 2003
(38% in 2004). The North West and East Midlands
also had high concentrations of cases involving
IDUs, 32% for both regions in 2003, falling to 25%
and 20%, respectively, in 2004. The London
region also reported relatively high numbers of
cases involving IDUs, 41% in 2003, falling to 20%
in 2004. In contrast, the South West (17%), West
Midlands (11%), North East (11%) and East of
England (5%) all had relatively fewer cases
involving IDUs over the 2 years. Spatial and
temporal analysis of cases involving IDUs re-
vealed 30% (138) that were diagnosed within
10 km and 30 days of another case, forming part
of one or more IDU clusters. In total, 87 clusters
were identiﬁed, with a median and mean size of
ﬁve cases (maximum 13).
Clinical presentations of cases
Among the 459 cases involving IDUs, 96% (442)
had positive blood cultures, higher than the
proportion in non-IDUs (90%; v2 (1 df) = 19.69;
p <0.001). Skin and soft tissue isolates were
cultured with similar frequency in both groups,
in 15% of IDUs and 17% of non-IDUs. Clinical
information was available for all but three of the
IDUs and two of the non-IDUs (Table 1). A
similar proportion of both groups had a dissem-
inated infection without obvious clinical focus,
22% of IDUs and 20% of non-IDUs. Among the
focal sites for infection, skin and soft tissue were
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Fig. 2. Seasonal pattern of date of
diagnosis of severe Streptococcus
pyogenes infection in injecting drug
users (IDUs) and non-IDUs, UK
2003–2004.
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Fig. 3. Geographical distribution of cases of severe Strep-
tococcus pyogenes infection in injecting drug users, UK
2003–2004.
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the most common in both groups, although they
were slightly more frequent in non-IDUs (46%)
than in IDUs (37%). Abscesses were substantially
more common in IDUs (18%) than in non-IDUs
(2%). Cardiac infections (endocarditis, myocardi-
tis and pericarditis) were reported in 7% of IDUs,
as compared to 1% in non-IDUs. Deep vein
thrombosis was similarly more common in IDUs
(6%) than in non-IDUs (<1%).
Respiratory tract infections were reported with
similar frequency in both groups (Table 1),
although pneumonia was slightly more common
in IDUs (14%) than in non-IDUs (11%), and twice
as common in IDUs as in non-IDUs of a similar
age (15–44 years old, 7%; v2 (1 df) = 9.51;
p 0.002). Multivariable analysis of data from all
cases indicated a three-fold increased likelihood
of pneumonia in IDUs as compared to non-IDUs
(OR 3.00, 95% CI 1.63–5.51, p < 0.001). Other
factors found to independently predict develop-
ment of pneumonia were diagnosis in December
(OR 2.04, 95% CI 1.06–3.92, p 0.032) as compared
to diagnosis in January, and age of 50–59 years
(OR 2.01, 95% CI 1.03–3.92, p 0.04) or 70–
79 years (OR 2.02, 95% CI 1.09–3.77, p 0.026) as
compared to a 0–10-year old reference group.
Patients infected with an emm ⁄M83 strain were
found to have a signiﬁcantly lower risk of pneu-
monia (OR 0.38, 95% CI 0.16–0.89, p 0.027) than
patients infected with other emm ⁄M types, with
emm ⁄M83 being identiﬁed in 16% of IDUs
with pneumonia as compared to 23% of IDUs
with other clinical presentations.
Relatively fewer IDUs developed STSS as
compared to non-IDUs (Table 1). Seven-day
attributable mortality was substantially lower
in IDUs than in non-IDUs (6% vs. 21%), even if
restricted to cases 15–44 years of age (5% vs.
10%; v2 (1 df) = 6.32; p 0.012). Comparison
of clustered and non-clustered IDUs revealed
more respiratory tract infections (18% vs. 10%;
v2 (1 df) = 4.71; p 0.03) among the latter group,
in particular pneumonia, which was diag-
nosed in 17% of non-clustered IDUs as com-
pared to 8% of clustered IDUs (v2 (1 df) = 5.68;
p 0.017).
Additional risk factors
Additional information concerning predisposing
factors is reported for the IDU group in Table 2.
IDU cases clustered with other IDUs were more
likely to have lesions and wounds to the skin
(19% as compared to 12% in non-clustered IDUs).
Substantially more of the clustered IDUs were
admitted from an institution of some kind (15%),
primarily hostels (11%), than their non-clustered
counterparts (1%).
emm ⁄M types of S. pyogenes isolates
Corresponding isolates were received for 327 of
the 459 IDUs (71%), and 1431 (77%) of non-IDUs.
In total, 44 emm ⁄M types were present among the
327 IDU isolates, as compared to 61 among the
1431 non-IDU isolates. The distribution of emm ⁄M
types was markedly different between the two
groups (Fig. 4); most notably, there was a high
proportion of emm ⁄M83 strains in IDU infections,
constituting 22%, and only 2% in non-IDU
infections (v2 (1 df) = 186.07, p <0.001); 70% of
all infections caused by emm ⁄M83 were in IDUs.
The following types were identiﬁed only in IDUs:
two cases each of emm ⁄M88 and emmst94, and one
case each of emm ⁄M25, emm ⁄M27, emm ⁄M92,
emmst102 and emmst4986. The ﬁrst and second
most common types in non-IDUs, emm ⁄M1 and
Table 1. Clinical presentation and outcome in injecting
drug users (IDUs) and non-IDUs diagnosed with severe
Streptococcus pyogenes infection, UK 2003–2004
IDUs Non-IDUs
Number
(%)
Number
(%)
Clinical presentations
Skin ⁄ soft tissue infection 167 (37) 838 (46) v2 (1 df) = 12.13; p <0.001
Cellulitis 140 (31) 659 (36)
Necrotizing fasciitis 13 (3) 112 (6)
Abscess 82 (18) 35 (2) v2 (1 df) = 194.75; p <0.001
Bacteraemia with
no deﬁned focus
99 (22) 371 (20)
Respiratory tract
infection
73 (16) 301 (16)
Pneumonia 64 (14) 200 (11)
Empyema 5 (1) 14 (1)
Other lower respiratory
tract infection
8 (2) 25 (1)
Upper respiratory
tract infection
1 (<1) 81 (4)
Septic arthritis 45 (10) 146 (8)
Cardiac infection 30 (7) 17 (1) v2 (1 df) = 58.08; p <0.001
Deep vein thrombosis 26 (6) 6 (<1) v2 (1 df) = 76.61; p <0.001
Acute abdomen 6 (1) 39 (2)
Puerperal sepsis 1 (<1) 57 (3)
Meningitis 1 (<1) 32 (2)
Other clinical markers*
Streptococcal toxic
shock syndrome
11 (2) 175 (10) v2 (1 df) = 24.85; p <0.001
Admittance to intensive
care unit
33 (8) 386 (23) v2 (1 df) = 45.74; p <0.001
Surgical
intervention
74 (23) 369 (26)
Mortality within 7 days 21 (6) 332 (21) v2 (1 df) = 45.97; p <0.001
Total 456 (100) 1841 (100)
Clinical information available for 456 and 1841 IDUs and non-IDUs respectively,
except ICU admission (402, 1652), surgery (323, 1421) and mortality (367, 1615)
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emm ⁄M3, were relatively uncommon in IDUs (3%
and 2% of isolates, respectively).
A greater diversity of emm ⁄M types was appar-
ent among the 83 clustered IDUs from whom
isolates were available than among the 244
non-clustered IDUs from whom isolates were
available, with an average of three isolates per
type for the clustered cases as compared to six per
type for the non-clustered cases. Types emm ⁄M44
(5% vs. 1%; v2 (1 df) = 5.50, p 0.02), emm ⁄M68
(4% vs. 0%; v2 (1 df) = 8.90, p 0.003), emm ⁄M81
(8% vs. 2%; v2 (1 df) = 5.79, p 0.016) and
emm ⁄M93 (2% vs. 0%; v2 (1 df) = 5.92, p 0.015)
were over-represented among clusters, whereas
emm ⁄M89 (0% vs. 7%; v2 (1 df) = 5.72, p 0.017)
was under-represented. For 67 (77%) of the 87
individual IDU clusters, emm ⁄M typing results
were available from isolates from more than one
member of the cluster. Of these 67 clusters, only
three involved a single type: one cluster of three
emmstNS1033 cases (two isolates); and two further
clusters of two emm ⁄M83 cases.
DISCUSSION
The commencement of the Strep-EURO pro-
gramme was fortuitous, as it has captured a
wealth of information pertaining to an interest-
ing phenomenon, an upsurge in severe S. pyog-
enes cases in IDUs in the UK. Prior surveillance
indicated consecutive yearly increases in rates of
severe S. pyogenes infection [11], which peaked
at 3.53 per 100 000 population in 2003, the
beginning of the data collection period for the
2-year Strep-EURO study [7]. Infections in IDUs
consequently increased during the early 2000s,
even beyond the increase in non-IDUs [6].
Table 2. Additional risk factors reported for injecting
drug users (IDUs) with severe Streptococcus pyogenes
infection, UK 2003–2004
Clustered
IDUs
Non-clustered
IDUs
Number
(%)
Number
(%)
Skin lesion ⁄wound 26 (19) 37 (12) v2 (1 df) = 4.36; p 0.037
Injection site 11 (8) 14 (4)
Abscess 12 (9) 19 (6)
Trauma 4 (3) 8 (3)
Chronic wound 0 (0) 2 (1)
Surgery 0 (0) 1 (<1)
Insect bite 0 (0) 1 (<1)
Skin infection 0 (0) 1 (<1)
Burns 0 (0) 1 (<1)
Rash 0 (0) 1 (<1)
Chronic infections
HIV ⁄AIDS 2 (1) 2 (1)
Hepatitis 3 (2) 4 (1)
Admitted from
an institution*
16 (15) 3 (1) v2 (1 df) = 24.38; p <0.001
Homeless hostel 12 (11) 1 (<1)
Hospital ⁄psychiatric unit 4 (4) 0 (0)
Substance misuse service 0 (0) 1 (<1)
Prison 1 (1) 0 (0)
Other risk factors
Alcoholism 6 (4) 7 (2)
Contact with individual
with S. pyogenes infection
3 (2) 4 (1)
Pregnancy-related
risk factor
0 (0) 5 (2)
Homeless status 4 (3) 1 (<1) v2 (1 df) = 5.25; p 0.022
Diabetes 1 (1) 1 (<1)
Healthcare-associated
infection
0 (0) 1 (<1)
Non-steroidal
anti-inﬂammatory drugs
0 (0) 1 (<1)
Cardiovascular disease 1 (1) 0 (0)
Total 136 (100) 320 (100)
*Information available for 334 cases
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The Strep-EURO programme conﬁrmed the
importance of IDUs as a group at risk for
severe S. pyogenes infections in the UK, with
20% of the cases being identiﬁed as IDUs, rising
to 52% of those aged 15–44 years. Comparison
with the other ten participating countries
showed this group to be substantially larger in
the UK, with 6% or fewer of the cases in any
other country being IDUs [8]. Interestingly, a
similar upsurge in IDU-related severe S. pyoge-
nes infections was reported in Barcelona in 2003
[12]. Spain was not one of the 11 participants in
the Strep-EURO network [8].
The S. pyogenes infections in IDUs identiﬁed
during this study were broadly similar to infec-
tions in non-IDUs in terms of the range of clinical
manifestations. However, similar to ﬁndings from
a study in the USA [13], the prognosis seemed to
be better for IDUs, even if age was taken into
account. This may be linked to the decreased
likelihood of IDUs developing STSS as compared
to non-IDUs, STSS being associated with a high
risk of mortality [7], or it may be explained by
differences in the strains causing disease in IDUs
as compared to those causing disease in non-
IDUs. This may in turn be a reﬂection of a greater
natural immunity in IDUs, due to repeated
infection with S. pyogenes over time, rendering
IDUs more immunologically primed to respond
to such infections and thus less susceptible to the
strains commonly infecting the general popula-
tion. Further analysis of the factors associated
with mortality ought to be undertaken to deter-
mine a reason.
Analysis of temporal and spatial information
suggests a mixture of sporadic and clustered
infections in IDUs, with just under one-third
being potentially linked to another case. As the
overriding majority of clusters involved a combi-
nation of emm ⁄M types, it remains debatable
whether these should be considered to be truly
epidemiologically linked [14], although it is a
feature of S. pyogenes clusters in general that a
mixture of types is often identiﬁed [15–17].
Certain features allowed differentiation between
the sporadic and clustered cases. Non-clustered
cases were more likely to present with respiratory
tract infections, possibly indicating a risk proﬁle
different from that of clustered cases. Interest-
ingly, clustered IDUs were slightly more likely to
be admitted from an institution for the homeless,
which suggests either transmission within such
institutions or points to these cases being more
marginalized than other IDUs.
The range of emm ⁄M types and the wide-
spread geographical distribution, albeit with foci
in some parts of the UK, discounts the possibility
of a point source or propagated outbreak, indi-
cating an epidemic rise of infections among
IDUs. To an extent, this could be explained, in
light of the recent general rise in severe S. pyog-
enes infections seen in the UK and beyond [11],
by the possibility that IDUs were simply dispro-
portionately affected. Although the similar sea-
sonal patterns in infections seen in IDUs and
non-IDUs in 2003 lend some support to this
hypothesis, the emm ⁄M type distribution in
IDUs, which differed markedly from that in
non-IDUs, rather argues against the possibility of
a straightforward overspill from one subpopula-
tion to the other. Several emm ⁄M types were
found only among IDUs, with a novel emm type
(st2161) being found among IDUs in the UK just
prior to this study [18]. The explanation for the
change in the UK, therefore, remains unclear,
although the range of clinical manifestations in
IDUs, including respiratory infections, does not
favour an explanation wholly centred around
injecting itself, although this could increase the
incidence of infection in a core group, with
continued transmission through other routes.
The upsurge of severe S. pyogenes infection seen
in IDUs in Philadelphia between 1979 and 1989
was attributed to increases in cocaine injection
[13], which facilitates tissue necrosis through
localized vasoconstriction. This could explain the
rise seen in the UK, with anecdotal evidence
indicating the adoption of a new marketing
strategy on the part of UK drug dealers during
the 2000s to increase the demand for crack
cocaine, i.e. provision of free crack ‘rocks’ with
heroin purchases, allowing the two drugs to be
dissolved and injected together (‘speedballing’).
An increase in cocaine use via injection would
also explain the rise in outbreaks of anaerobic
infections seen in the UK [2–4]. Given the illicit
nature of injecting drug use, reliable data on
trends in drug consumption over this period are
not available, although records of drug-related
deaths show an increase in cocaine-related
deaths between 2001 and 2003, whereas the
number of heroin ⁄morphine-related deaths de-
creased [19]. However, the regional pattern of
severe S. pyogenes infections in IDUs corresponds
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more to that of opioid use than to use of crack
cocaine per se, although data are not available for
injection of crack cocaine and heroin together
[20].
Alternative explanations for this upsurge in
IDUs include an increase in sharing of injecting
equipment, although national monitoring in the
UK has not provided evidence of this [21]. Other
possible explanations include an increase in the
numbers of IDUs, which would be difﬁcult to
prove, or an increase in IDUs who are susceptible
to infection, e.g. due to human immunodeﬁciency
virus-related immunocompromised status. Data
from the national seroprevalence monitoring
programme in the UK did show a slight increase
in anti-HIV prevalence during the early 2000s
although remaining below 2% [21]. Seropreva-
lence data indicated a possible increase in trans-
mission of hepatitis C and B viruses during this
time, possibly reﬂecting a deterioration in injec-
tion hygiene. Contamination of the drug supply
chain can probably be discounted as an explana-
tion, as it is difﬁcult to envisage a mechanism
through which contamination could account for
the diversity of strain types seen. Analyses of
drug samples from outbreaks of S. pyogenes infec-
tion have tended to fail to culture the organism
[12,22], and the process of mixing heroin or crack
cocaine with citrates (to dissolve them prior to
injecting) would tend to kill the organism.
As well as the reasons behind the increase in
cases of severe S. pyogenes infection among IDUs
in the UK remaining unclear, the cause of the
decrease in infection among IDUs in 2004 is also
subject to debate. Although data of the type
used for this study are not available beyond
2004, subsequent referrals of S. pyogenes isolates
from IDUs showed a dramatic decline after 2004
[21]. Frontline drug services for IDUs increased
during the early 2000s to mid-2000s, which
could have resulted in a reduction in illicit
injecting, because more users took advantage of
the availability of opioid substitution therapy,
and could also have increased the use of sterile
injecting equipment [23]. In recognition of the
emerging problem of severe S. pyogenes infec-
tions among IDUs, local public health cam-
paigns were mounted during this period, which
may well have succeeded in abating this
epidemic through early recognition and prompt
treatment of superﬁcial infections. An alter-
native explanation might be that the reasons
behind the increase in IDUs lessened over this
period. Continued monitoring clearly remains
essential to identify further resurgences of infec-
tion in this vulnerable population.
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